Good morning :)
$
₹
Sellas Life Sciences Group Inc

Sellas Life Sciences Group Inc

SLS

NASDAQ
Asset Logo

Sellas Life Sciences Group Inc

SLS

NASDAQ
$7.8414.20% (-1.29)
$
₹
$7.8414.20% (-1.29)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Biotechnology

Small Cap

With a market cap of $1.8B the stock is ranked 2267

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

12.54
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-0.21
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 2 analysts reports

Buy
2 analysts
Hold
0 analyst
Sell
0 analyst

Price Upside

+312.44%

Earnings Growth

+20%

Rev. Growth

—

See Detailed Forecast

Company Profile

Company Profile

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
49.14
49.14
1Y Return
36.01%
36.01%
Buy Reco %
79.31
79.31
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
28.64
28.64
1Y Return
50.65%
50.65%
Buy Reco %
35.29
35.29
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
42.33%
42.33%
Buy Reco %
78.57
78.57
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
35.59
35.59
1Y Return
30.09%
30.09%
Buy Reco %
81.25
81.25
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
P/E Ratio
21.51
21.51
1Y Return
40.33%
40.33%
Buy Reco %
67.85
67.85
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Higher price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 312.44% growth, versus a trailing 3-year CAGR of 101.32%.

2026
Current$7.88Baseline
Analyst Target - 1 year
Target$32.5+312.44%

All values in $

202220232024202520262027$9.64$18.34$27.05Target+312.44%
2026
Current$7.88Baseline
Analyst Target - 1 year
Target$32.5+312.44%

All values in $

Earnings Per Share Forecast

Earnings Per Share Forecast

2025
Current$-0.25Baseline
Forecast for Dec 2026
High$-0.2+20%
Average$-0.2+20%
Low$-0.2+20%

All values in $

202120222023202420252026-1.33-1.61-1.36-0.52-0.25Low+20%Average+20%High+20%
2025
Current$-0.25Baseline
Forecast for Dec 2026
High$-0.2+20%
Average$-0.2+20%
Low$-0.2+20%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

-6.7
-7.6
-8.4
-9.6
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue0000000000
Net Income-9.56-7.47-7.10-6.73-5.81-6.60-6.79-7.65-8.40-9.60
Net Profit Margin----------
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Sellas Life Sciences Group Inc -12.54-
AbbVie Inc49.1450.450.58
Amgen Inc28.6421.552.77
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare SLS with any stock or ETF
Compare SLS with any stock or ETF
Comparing from
SLS
ABBV
AMGN
Loading...

Frequently asked questions

  1. Sellas Life Sciences Group Inc (SLS) share price today is $7.84 as of November 6, 2026 at 2:29 AM IST. The stock touched a day high of $8.99 and a day low of $7.84.

  2. Sellas Life Sciences Group Inc stock trades on NASDAQ under the ticker symbol SLS.

  3. Sellas Life Sciences Group Inc's market capitalization is $1.79B as of November 6, 2026 at 2:29 AM IST.

  4. Sellas Life Sciences Group Inc's price-to-earnings (P/E) ratio is N/A as of November 5, 2026.

  5. Sellas Life Sciences Group Inc's price-to-book (P/B) ratio is 12.54 as of November 5, 2026.

  6. Yes, You can buy Sellas Life Sciences Group Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Sellas Life Sciences Group Inc shares in three steps: 1. Search Sellas Life Sciences Group Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Sellas Life Sciences Group Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Sellas Life Sciences Group Inc (SLS) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 1.2751 shares at the current price of $7.84.

Loading...